Rallybio Corporation
Price Action
Technical Summary
STAGE 2 UPTRENDRallybio Corporation is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings growth of 13% provides fundamental context to the price action. Investors should exercise caution due to high volatility (141% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $16.00 | +0.40% | ABOVE |
| 50 SMA | $13.80 | +16.35% | ABOVE |
| 100 SMA | $10.79 | +48.82% | ABOVE |
| 150 SMA | $9.03 | +77.82% | ABOVE |
| 200 SMA | $7.96 | +101.73% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RLYB in an uptrend right now?
RLYB has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, RLYB is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is RLYB overbought or oversold?
RLYB's RSI (14) is 63. The stock is in neutral territory, neither overbought nor oversold.
Is RLYB outperforming the market?
RLYB has a Relative Strength (RS) Rating of 98 out of 99. Yes, RLYB is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is RLYB in its 52-week range?
RLYB is trading at $16.06, which is 92% of its 52-week high ($17.50) and 91% above its 52-week low ($0.58).
How volatile is RLYB?
RLYB has a Beta of 0.70 and 52-week volatility of 141%. It's less volatile than the S&P 500 - generally more stable.